Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2015
  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine 2012 - 2013
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Indiana University School of Medicine 2008
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2012 - 2013
• Research
• 

  Selected Grants

  • Array-818-202 2019 - 2024
  • MCC 19704 2019 - 2024
  • TOP 1705 2018 - 2023
  • SPI-POZ-202 2017 - 2022
  • M15-534 2017 - 2022
  • Adaptimmune SURPASS 2019 - 2021
  • A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance 2016 - 2021
  • mRNA-4157-P101 2017 - 2020
  • Adaptimmune MAGE A-4 2018 - 2020
  • Genentech GO29537 2015 - 2020
  • A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors 2015 - 2020
  • An Open label phase II study evaluatint Traztuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in patients who have advanced cancer 2016 - 2020
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2020
  • First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors 2014 - 2019
  • Adaptimmune MAGE 2018 - 2019
  • Bayer 16044 2017 - 2019
  • A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or G 2013 - 2019
  • Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2018
  • Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer 2015 - 2018
  • Lilly H9H-MC-JBEF 2016 - 2018
  • Blood-based Biomarker Profiling for TEW-7197 2016 - 2018
• 

  Industry Relationships

  • Astra Zeneca
  • Eli Lilly & Co.
  • Guardant Health
  • Merck
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Jung, Su Young, Ji Seob Yug, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Sunjin Hwang, Seong-Jin Kim, Eun Kyoung Chung, and Jangik I. Lee. “Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors..” Cancer Chemother Pharmacol, October 30, 2019. https://doi.org/10.1007/s00280-019-03979-z.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)..” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.
       Full Text  Link to Item
    • Marano, A. L., J. M. Clarke, M. A. Morse, A. Shah, W. Barrow, M. A. Selim, R. P. Hall, and A. R. Cardones. “Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy..” Br J Dermatol 181, no. 3 (September 2019): 580–83. https://doi.org/10.1111/bjd.17245.
       Full Text  Link to Item
    • Jung, Su Young, Sunjin Hwang, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Hukeun Lee, Neunggyu Park, Seong-Jin Kim, and Jangik I. Lee. “Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study..” Invest New Drugs, July 13, 2019. https://doi.org/10.1007/s10637-019-00835-y.
       Full Text  Link to Item
    • Tan, Irena, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, and Jeffrey M. Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study..” Transl Lung Cancer Res 8, no. 3 (June 2019): 258–67. https://doi.org/10.21037/tlcr.2019.04.03.
       Full Text  Link to Item
    • DeMaio, Andrew, Jeffrey M. Clarke, Rajesh Dash, Siby Sebastian, Momen M. Wahidi, Scott L. Shofer, George Z. Cheng, Xuechan Li, Xiaofei Wang, and Kamran Mahmood. “Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma..” J Bronchology Interv Pulmonol 26, no. 2 (April 2019): 96–101. https://doi.org/10.1097/LBR.0000000000000534.
       Full Text  Link to Item
    • Pabla, Sarabjot, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, et al. “Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients..” J Immunother Cancer 7, no. 1 (February 1, 2019). https://doi.org/10.1186/s40425-019-0506-3.
       Full Text  Link to Item
    • Shariff, Afreen Idris, Sohail Syed, Rebecca A. Shelby, Jeremy Force, Jeffrey Melson Clarke, David D’Alessio, and Leonor Corsino. “Novel cancer therapies and their association with diabetes..” J Mol Endocrinol 62, no. 2 (February 1, 2019): R187–99. https://doi.org/10.1530/JME-18-0002.
       Full Text  Link to Item
    • Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors..” J Immunother Cancer 7, no. 1 (January 24, 2019). https://doi.org/10.1186/s40425-018-0489-5.
       Full Text  Link to Item
    • Velikova, Galina, Linda Jane Williams, Sarah Willis, J Michael Dixon, Juliette Loncaster, Matthew Hatton, Jacqueline Clarke, Ian H. Kunkler, Nicola S. Russell, and Nicola S. MRC SUPREMO trial UK investigators. “Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial..” Lancet Oncol 19, no. 11 (November 2018): 1516–29. https://doi.org/10.1016/S1470-2045(18)30515-1.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Daniel J. George, Stacey Lisi, and April K. S. Salama. “Immune Checkpoint Blockade: The New Frontier in Cancer Treatment..” Target Oncol 13, no. 1 (February 2018): 1–20. https://doi.org/10.1007/s11523-017-0549-7.
       Full Text  Link to Item
    • Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab..” Clin Cancer Res 23, no. 24 (December 15, 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
       Full Text  Link to Item
    • Nayar, Gautam, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, and Peter E. Fecci. “Leptomeningeal disease: current diagnostic and therapeutic strategies..” Oncotarget 8, no. 42 (September 22, 2017): 73312–28. https://doi.org/10.18632/oncotarget.20272.
       Full Text  Link to Item
    • Bedoya, Armando, Kristen Glisinski, Jeffrey Clarke, Richard N. Lind, Charles Edward Buckley, and Scott Shofer. “Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases..” Am J Case Rep 18 (July 31, 2017): 842–46. https://doi.org/10.12659/ajcr.904416.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Xiaofei Wang, and Neal E. Ready. “Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?.” Transl Lung Cancer Res 4, no. 6 (December 2015): 804–8. https://doi.org/10.3978/j.issn.2218-6751.2015.05.03.
       Full Text  Link to Item
    • Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress..” Cancer J 21, no. 4 (July 2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.
       Full Text  Link to Item
    • Lyman, Gary H., Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014..” J Clin Oncol 33, no. 6 (February 20, 2015): 654–56. https://doi.org/10.1200/JCO.2014.59.7351.
       Full Text  Link to Item
    • Clarke, J. M., H. I. Hurwitz, and F. Rangwala. “Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective..” Cancer Treat Rev 40, no. 9 (October 2014): 1065–72. https://doi.org/10.1016/j.ctrv.2014.07.001.
       Full Text  Link to Item
    • Clarke, Jeffrey M., and Herbert I. Hurwitz. “Understanding and targeting resistance to anti-angiogenic therapies..” J Gastrointest Oncol 4, no. 3 (September 2013): 253–63. https://doi.org/10.3978/j.issn.2078-6891.2013.036.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, and Herbert I. Hurwitz. “Targeted inhibition of VEGF receptor 2: an update on ramucirumab..” Expert Opin Biol Ther 13, no. 8 (August 2013): 1187–96. https://doi.org/10.1517/14712598.2013.810717.
       Full Text  Link to Item
    • Lyman, Gary H., Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, Jeffrey M. Clarke, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update..” J Clin Oncol 31, no. 17 (June 10, 2013): 2189–2204. https://doi.org/10.1200/JCO.2013.49.1118.
       Full Text  Link to Item
    • Clarke, J. M., and A. J. Armstrong. “Novel therapies for the treatment of advanced prostate cancer..” Curr Treat Options Oncol 14, no. 1 (March 2013): 109–26. https://doi.org/10.1007/s11864-012-0222-4.
       Full Text  Link to Item
    • Clarke, Jeffrey M., and Herbert I. Hurwitz. “Ziv-aflibercept: binding to more than VEGF-A--does more matter?.” Nat Rev Clin Oncol 10, no. 1 (January 2013): 10–11. https://doi.org/10.1038/nrclinonc.2012.197.
       Full Text  Link to Item
    • Mis, L., and J. M. Clarke. “Ipilimumab-induced pneumonitis: A case report.” Journal of Pharmacy Technology 29, no. 2 (January 1, 2013): 94–98. https://doi.org/10.1177/875512251302900207.
       Full Text
    • Clarke, Jeffrey M., and Paul Helft. “Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature..” J Med Case Rep 4 (October 29, 2010). https://doi.org/10.1186/1752-1947-4-346.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Michael A. Morse, H Kim Lyerly, Timothy Clay, and Tayuka Osada. “Adenovirus vaccine immunotherapy targeting WT1-expressing tumors..” Expert Opin Biol Ther 10, no. 6 (June 2010): 875–83. https://doi.org/10.1517/14712591003798278.
       Full Text  Link to Item
    • Struck, A., T. Howard, E. G. Chiorean, J. M. Clarke, R. Riffenburgh, and H. R. Cardenes. “Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival (Journal of Surgical Oncology (2009) 100, 2, (144-148)).” Journal of Surgical Oncology 100, no. 5 (October 1, 2009). https://doi.org/10.1002/jso.21396.
       Full Text
    • Struck, Aaron, Thomas Howard, Elena G. Chiorean, Jeffrey M. Clarke, Robert Riffenburgh, and Higinia R. Cardenes. “Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival..” J Surg Oncol 100, no. 2 (August 1, 2009): 144–48. https://doi.org/10.1002/jso.21319.
       Full Text  Link to Item

  • Conference Papers

    • Lee, J. I., S. Y. Jung, J. S. Yug, E. K. Chung, V. L. Keedy, T. M. Bauer, J. M. Clarke, et al. “POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS..” In Clinical Pharmacology & Therapeutics, 105:S103–S103. WILEY, 2019.
       Link to Item
    • Tan, Irena, Tom Stinchcombe, Neal E. Ready, Michael B. Datto, Rebecca J. Nagy, Lin Gu, and Jeffrey Melson Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study..” In Journal of Clinical Oncology, 36:e21222–e21222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e21222.
       Full Text
    • Patel, Sandip Pravin, Scott Morris, Young Kwang Chae, and Jeffrey Melson Clarke. “RNA turbulence by tumor type: Overexpression of actionable mRNA signaling pathways by histology..” In Journal of Clinical Oncology, 35:e23213–e23213. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e23213.
       Full Text
    • Yi, John, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, Mark W. Onaitis, Chelsae Dumbauld, et al. “Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC)..” In Journal of Clinical Oncology, Vol. 35. AMER SOC CLINICAL ONCOLOGY, 2017.
       Link to Item
    • Demaio, A., R. C. Dash, S. Sebastian, J. M. Clarke, M. M. Wahidi, and K. Mahmood. “Comprehensive Genetic Mutation Analysis On Pleural Effusions Related To Lung Adenocarcinoma.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.
       Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL)..” In Journal of Clinical Oncology, 34:e15013–e15013. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e15013.
       Full Text
    • Clarke, Jeffrey Melson, Herbert Pang, Mark D. Starr, Ace Joseph Hatch, Hedy Lee Kindler, Eileen Mary O’Reilly, Federico Innocenti, Alan P. Venook, Herbert Hurwitz, and Andrew B. Nixon. “Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)..” In Journal of Clinical Oncology, 33:306–306. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.306.
       Full Text
    • Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial..” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.